UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...